Finance

Lists
Why is BCCOY up 39,45%?
Dive Deeper
BCCOY:OTCMKTS
BICO Group 4 ADR Representing Ord Shs
USD 0,71
+39,45%
(+0,20) 1D
14 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCCOY...
Open
USD 0,71
High
USD 0,71
Low
USD 0,71
Mkt. cap
1,70 mjd
Avg. vol.
13,00
Volume
200,00
52-wk high
USD 0,75
52-wk low
USD 0,35
Beta
1,95
Shares outstanding
276,30 m
No. of employees
554
Open
USD 0,71
High
USD 0,71
Low
USD 0,71
Mkt. cap
1,70 mjd
Avg. vol.
13,00
Volume
200,00
52-wk high
USD 0,75
52-wk low
USD 0,35
Beta
1,95
Shares outstanding
276,30 m
No. of employees
554
News stories
From web sources and news partners
Profile
Bico Group is a Swedish bioconvergence company that designs and supplies technologies and services to enhance biology research. It focuses on commercializing technologies for life science research as well as bioprinting. Bico Group began by producing bio-inks and bioprinters for culturing different cell types to enable applications like patient-derived implants. Bico Group was the first company to provide a standardized bio-ink product for sale over the internet. The company has ongoing collaborations with organizations including AstraZeneca, MedImmune, MIT and Takara Bio, and its bioprinters are used for research at Harvard University, Merck, Novartis, the U.S. Army, Toyota, Johnson & Johnson and more. Wikipedia
About BICO Group 4 ADR Representing Ord Shs
CEO-
Employees554
Founded27 Jan. 2016
Headquarters-
SectorHealth care
Websitebico.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
386,90 m
451,30 m
329,90 m
336,10 m
Cost of goods sold
174,20 m
215,90 m
151,30 m
136,90 m
Cost of revenue
174,20 m
215,90 m
151,30 m
136,90 m
Research and development expenses
50,10 m
48,80 m
49,30 m
56,90 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
204,10 m
204,30 m
224,80 m
179,70 m
Operating expense
259,60 m
249,50 m
269,80 m
229,40 m
Total operating expenses
433,80 m
465,40 m
421,10 m
366,30 m
Operating income
-46,90 m
-14,10 m
-91,20 m
-30,20 m
Other non operating income
-
-8,40 m
-
-100,00 k
EBT including unusual items
-1,11 mjd
-57,00 m
-127,50 m
-34,90 m
EBT excluding unusual items
-73,30 m
-73,30 m
-105,30 m
-23,60 m
Income tax expense
-2,20 m
2,20 m
3,80 m
2,30 m
Effective tax rate
0,20%
-3,86%
-2,98%
-6,59%
Other operating expenses
5,40 m
-3,60 m
-4,30 m
-7,20 m
Net income
-612,70 m
-55,00 m
-131,30 m
-37,20 m
Net profit margin
-158,36%
-12,19%
-39,80%
-11,07%
Earnings per share
-
-
-
-
Interest and investment income
2,70 m
212,00 m
9,10 m
20,30 m
Interest expense
-29,10 m
-11,90 m
-23,20 m
-13,60 m
Net interest expenses
-26,40 m
200,10 m
-14,10 m
6,70 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,04 mjd
48,40 m
-20,10 m
27,00 m
Gain or loss from assets sale
-
-480,30 m
-
-
AI content may include mistakes. Learn more
Google-programme